Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (Sunitinib)
2010-024621-20Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sunitinib in pheochromocytoma, malignant paraganglioma and Paraganglioma (PGL), sponsored by Gustave Roussy. Primary endpoint: Progression-free survival at 12 months. Started Feb 2013; status: active.
02
Drugs
sunitinib
03
Conditions
pheochromocytomamalignant paragangliomaParaganglioma (PGL)
Beyond the preview
Go deeper on 2010-024621-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024621-20.